Becton Dickinson (BDX) and ChemoGLO announced a strategic collaboration to advance hazardous drug contamination testing in health care setting.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson price target raised to $210 from $197 at Morgan Stanley
- Becton Dickinson Faces Risks in Biosciences and Diagnostic Merger with Waters
- Becton Dickinson Onclarity HPV Assay, BD Viper receive WHO prequalification
- Starboard takes new stake in Bill Holdings, exits Pfizer position
- Becton Dickinson price target lowered to $202 from $211 at RBC Capital